Florida cracks down on deadly 7-OH drug after 587 overdose deaths
Florida cracks down on deadly 7-OH drug after 587 overdose deaths
Florida cracks down on deadly 7-OH drug after 587 overdose deaths
A dangerous opioid-like chemical has been tied to hundreds of overdose deaths in Florida. Known as 7-OH, the substance has prompted urgent action from authorities to curb its spread. The drug is now classified as a Schedule I substance under emergency rules. Since 2013, 7-OH has been linked to at least 587 overdose deaths across Florida. The chemical acts on opioid receptors, leading to respiratory depression, addiction, and severe withdrawal symptoms. Its presence in products sold at gas stations and vape shops has raised alarms.
Brands such as Hydroxy, 7Tabz, and 7OHMZ have sold concentrated versions of the drug. In response, Florida introduced an emergency rule to limit 7-OH content to 1 milligram per gram or millilitre in products. Since the rule took effect, over 23,000 illegal packages have been seized from retailers.
The FDA has warned consumers to avoid 7-OH products entirely. The agency has not approved them for any medical use and has issued warning letters to companies distributing them illegally. The emergency classification now allows felony-level arrests and the shutdown of illegal sellers. The crackdown aims to reduce exposure and overdose cases, which have been rising in recent years. The classification as a Schedule I substance strengthens legal measures against its sale. Authorities continue to monitor and remove illegal products from circulation.
German nursing care reform faces backlash over financial risks ahead of cabinet review
A €1.8 billion annual burden on pensions. Half of care home residents at risk of welfare. Why Germany's reform is under fire—and what happens next.
Region transforms healthcare with new hospitals and modernized rural clinics
From high-tech hospitals to rural clinic revamps, this region is rewriting its healthcare story. Thousands of patients will soon benefit from expanded access and cutting-edge facilities.
FDA panel with industry ties to review peptide injection safety in July
A controversial FDA panel, stacked with doctors profiting from peptides, will decide their fate. Will science or business interests shape the outcome?
Nursing homes in crisis as low wages spark staffing shortages and delays
Thousands wait for care as underpaid staff push nursing homes to the brink. Will strikes force a pay rise—or collapse the system further?